Theralase Technologies Inc. V.TLT

My read

[DJDawg]

It is not the most amazing release as I'm confused as to the pre-BTD situation. The swimmers plot shows that Ruvidar is still an effective tool that can offer one or two and done option to many. In my opinion Ruvidar is still far superior to alternatives.

Nothing in the release is a positive catalyst for some price spike in the next days or weeks. I hope that most of us will do what we have always done which is hold on and wait patiently.

Recall that MP sent out a release recently that caused a big price rally. I pasted below.

It will be interesting to see if anything comes out of the woodwork to validate the hope MP created in the release below. I have said many times that the science is awesome (antiviral, gbm, nsclc, bladder, vaccine) but I've always been frustrated by the management. There are boston biotechs that have done startups with way worse data and have had zero trouble getting money and momentum. TLT is such a contrast. I fear that we are all at the mercy of RDW not wanting to give up any control or percent ownership. The alternative is that they have great data and yet cannnot convince anyone beyond the investor on this board to be excited. How can that be?

I hope (wishful) that there is a surprise announcement in the coming weeks about something that changes our current plateau.

It was very recently that MP said that they intentionally are only doing a small raise. I hope that there was something behind that statement as another PP in Jan at a low price will not get that much interest I suspect.

------

We continue to move forward on our primary objectives:

1. Completing the enrolment of our clinical study by end of 2024, early next year.  We are in the process of adding 5 additional sites to accelerate our enrolment.
2. Commencing a strategic partnership.  We have several ongoing discussions that continue to develop.
3. Receiving approval for a government program that could assist with our capitalization objective; this decision could come at any time between now and the end of the year.
4. Securing capital from an institutional investor, Family Office, or large retail investor.  There are several interested firms, we may have something secured in the next few weeks, but if not, we will move towards a private placement shortly whether they participate or not.

Let me know if you would like to discuss any of the above.

[charlierock]

Another missed timeline. Can't say I'm surprised considering management's track record. Maybe BTD sometime in the next  6 - 24 months, who knows. The science is still great so more patience required till we get to the promised land but on the other hand, what's the FDA going to look like when the new clown show administration takes over.  

[TommyNickels]

That email was a pump. Desperate measure to raise cash.  They got 600,000$. Doesn't even cover 30 days of expenses.  I am grateful I don't own any shares. Going to be a very red day.

[Alamir1111]

Study II commenced in April 2019 with an estimated completion time of approximately 8 years and an estimated cost of approximately $CAN 100 million. The timing and cost may vary significantly depending on numerous factors; including: number of Clinical Study Sites (" CSSs ") enrolling and treating patients, patient enrollment rates in total and at each CSS, patient compliance

[Maxcitrac]

DJDawg. If this MP is legitimate; I like number three. Theralase: We continue to move forward on our primary objectives: 3. Receiving approval for a government program that could assist with our capitalization objective; this decision could come at any time between now and the end of the year. The phrasing and the small $600.000 PP raise, seem to indicate that Theralase already know that the